Marcellin, PatrickBonino, FerruccioLau, GeorgeFarci, PatriziaYurdaydin, C.Piratvisuth, TeerhaJin, R.Hadziyannis, Stephanos J.Lu, ZhimengPopescu, Madalina2022-11-012022-11-012006Marcellin, P. vd. (2006). ''The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment''. Journal of hepatology, 44(Suplement 2), S275-S275.0168-8278https://doi.org/10.1016/S0168-8278(06)80744-0https://www.sciencedirect.com/science/article/pii/S0168827806807440http://hdl.handle.net/11452/29287Bu çalışma, 26-30 Nisan 2006 tarihleri arasında Vienna[Avusturya]’da düzenlenen 41. Annual Meeting of the European-Association-for-the-Study-of-the-Liver’da bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessGastroenterology & hepatologyThe majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatmentMeeting Abstract000237328100744S275S27544Supplement 2Gastroenterology & hepatology